"considerations and challenges include scaling up good manufacturing practice (GMP) production"
Then I think of J&J and its 15M ruined doses, and then wonder whether pharma co's should provide better access to rank & file managers into scientific journals, particularly stuff they are known to be building.
"considerations and challenges include scaling up good manufacturing practice (GMP) production"
Then I think of J&J and its 15M ruined doses, and then wonder whether pharma co's should provide better access to rank & file managers into scientific journals, particularly stuff they are known to be building.
https://www.dailymail.co.uk/health/article-9486801/Emergent-...